Clostridioides difficile
Clostridioides difficile, also known as C. diff, is a Gram-positive, spore-forming bacterium that causes serious diarrheal infections and inflammation of the colon, and may also contribute to colon cancer. This anaerobic, motile bacterium is ubiquitous in nature, thriving in soil and producing toxins that can lead to severe health issues, particularly in the human gastrointestinal tract.
Health Outcomes
- Accelerated Diarrhea Recovery
- Accurate Enumeration of Viable Probiotic Bacteria
- Adjusted Intestinal Microbiota Abundance
- Adverse Events from Probiotics
- Alleviated Diarrhea
- Altered Antibiotic Susceptibility
- Altered Bacterial Proportions
- Altered Colonic Microbial Communities
- Altered Dominant Intestinal Bacterial Composition
- Altered Enteric Bacterial Flora
- Altered Faecal Microbiota Profile
- Altered Gastrointestinal Health Post-Infection
- Altered Gastrointestinal Microbiome Composition
- Altered Gut Microbial Community
- Altered Microbial Population Composition
- Altered Microbial Profile
- Altered Pathogenic Bacterial Biomolecules
- Altered Stool Microbiota Profile
- Antimicrobial Food Preservation
- Balanced Gut Microbiome
- Balanced Intestinal Microflora
- Carriage of Toxin-Producing Clostridium Difficile
- Changed Stool Consistency
- Colonization of Fibrolytic Bacteria
- Colonization of the Intestine
- Confirmed Safety of Oral Probiotic Administration
- Delayed Onset of First Diarrhea Episode
- Detected Antimicrobial Resistance Genes
- Disrupted Bacterial Cell Membranes
- Disrupted Gut Microbiota Distribution
- Disrupted Microbial Cell Membrane Integrity
- Effective Gastroenteritis Treatment
- Effectiveness Compared to Commercial Probiotic
- Elevated Viable Bacterial Counts
- Enhanced Adhesion to Colon Cells
- Enhanced Antibacterial Effect
- Enhanced Bacterial Growth
- Enhanced Bactericidal Activity
- Enhanced Beneficial Bacteria in Intestinal Microbiota
- Enhanced Diversity of Protective Bifidobacterial Populations
- Enhanced Gut Microbiota Stability
- Enhanced Immune Response Against Specific Bacteria
- Enhanced Microbiota Recovery
- Enhanced Pathogen Protection
- Enhanced Probiotic Gut Adhesion
- Enhanced Probiotic Presence
- Enhanced Resistance to Pathogenic Bacteria
- Fecal Contamination
- Gastrointestinal Tract Colonization
- High Viability of Probiotic Lactobacillus crispatus BC4 in Cheese
- Improved Antagonistic Activity Against Undesirable Microorganisms
- Improved Antibiotic Resistance Outcomes
- Improved Antibiotic Susceptibility
- Improved Antibiotic-Associated Diarrhea
- Improved Bacterial Survival Rate
- Improved Beneficial Intestinal Bacteria
- Improved Colonization Efficiency
- Improved Colonization Resistance
- Improved Colonization Resistance to Pathogens
- Improved Cure Rate
- Improved Diarrhea Symptoms
- Improved Efficacy of Diarrhea Treatment
- Improved Fecal Microbiota
- Improved Fecal Microbiota Diversity
- Improved Fecal Odor
- Improved Food Safety
- Improved Gastrointestinal Infection Outcomes
- Improved Gastrointestinal Microbiome Balance
- Improved Gastrointestinal Pathogen Inhibition
- Improved Growth of Beneficial Bacteria
- Improved Gut Flora Modulation
- Improved Gut Protection
- Improved Host Health
- Improved Intestinal Defense Mechanism
- Improved Intestinal Flora Balance
- Improved Intestinal Flora Diversity
- Improved Intestinal Innate Immunity
- Improved Intestinal Microbiota Balance
- Improved Intestinal Microflora
- Improved Intestinal Microflora Balance
- Improved Intestinal Microflora Diversity
- Improved Lactobacillus Abundance
- Improved Macroscopic Colonic Damage
- Improved Management of Acute Diarrhoea
- Improved Management of Acute Gastroenteritis
- Improved Management of Diarrhea
- Improved Microbial Identification
- Improved Microbial Safety
- Improved Probiotic Function
- Improved Probiotic Functionality
- Improved Probiotic Safety
- Improved Probiotic Suitability
- Improved Quality of Probiotic Food Products
- Improved Recovery from Antibiotic-Associated Diarrhea
- Improved Recovery from Diarrhea
- Improved Resistance to Infections
- Improved Resistance to Intestinal Pathogens
- Improved Serum-Mediated Pathogen Killing
- Improved Strain-Level Competitive Fitness
- Improved Survival of Probiotic Bacteria
- Improved Survival of Probiotic Strains During Antibiotic Use
- Improved Tolerance to High Doses of Probiotics
- Improved Treatment Safety
- Incidence of Hospital-Acquired Diarrhea
- Increased Abdominal Symptoms in Children Taking Antibiotics
- Increased Abundance of Antibiotic Resistance Genes
- Increased Abundance of Peptostreptococcaceae
- Increased Abundance of Specific Bacterial Species
- Increased Adverse Event Incidence
- Increased Adverse Events
- Increased Antagonistic Activity Against Undesirable Microorganisms
- Increased Anti-toxin A Levels
- Increased Antibacterial Activity
- Increased Antibacterial Activity Against Pathogens
- Increased Antibacterial Compound Production
- Increased Antibiotic Sensitization
- Increased Antimicrobial Resistance
- Increased Bacillus Species Populations
- Increased Bacterial Membrane Permeability
- Increased Bacterial Proliferation
- Increased Bacterial Survival
- Increased Beneficial Bacterial Colonization
- Increased Beneficial Bacterial Counts
- Increased Beneficial Gut Microbiota Abundance
- Increased Bifidobacterium Levels
- Increased Cecal Lactobacilli Levels
- Increased Colon Lactobacilli
- Increased Colonic Lactobacilli Levels
- Increased Colonization by Administered Strain
- Increased Cure Rate of Diarrhea by Day 3
- Increased Diarrhea Incidence
- Increased Diarrhoea-Free Rate in Children After 72 Hours
- Increased Dispersal of Pathogenic Bacteria
- Increased Economic Burden Due to Higher Antibiotic Costs
- Increased Effectiveness Against Antibiotic-Resistant Bacteria
- Increased Endogenous Bifidobacteria Levels
- Increased Fecal Acidity Similar to Breastfed Infants
- Increased Fecal Bifidobacteria
- Increased Fecal Lactate Concentration
- Increased Fecal Lactic Acid
- Increased Fecal Lactic Acid Bacteria Counts
- Increased Fecal Lactic Acid Concentration
- Increased Fecal Lactobacilli Content
- Increased Fecal Lactobacilli Levels
- Increased Fecal Lactobacilli Population
- Increased Fecal Lactobacilli Viability
- Increased Fecal Lactobacillus reuteri Concentration
- Increased Fecal Lactobacillus reuteri Levels
- Increased Fecal Moisture
- Increased Fecal Moisture Content
- Increased Fecal Output
- Increased Fecal Probiotic Bacteria
- Increased Fecal Probiotic Strains
- Increased Fecal Score
- Increased Fecal Spore Counts
- Increased Frequency of Loose or Watery Stools
- Increased Gastrointestinal Tract Colonization
- Increased Gut Microbial Supplementation
- Increased IgA-Inducing Activity
- Increased Immunity to Gut-Acquired Infections
- Increased Inhibition of Pathogenic Bacteria
- Increased Interest in Probiotic Supplements
- Increased Intestinal Cell Adherence
- Increased Lactic Acid Bacteria Levels
- Increased Lactobacillus Levels
- Increased Lactobacillus Population
- Increased Lactobacillus acidophilus in Crop at 14 Days
- Increased Length of Hospitalization Due to Vancomycin Resistance
- Increased Levels of Lactobacillus Paracasei/Casei
- Increased Microbiota Engraftment
- Increased Persistence of Probiotics in Fecal Matter
- Increased Population of Beneficial Gut Bacteria
- Increased Probiotic Activity
- Increased Probiotic Bacteria Abundance
- Increased Probiotic Bacteria Colonization
- Increased Probiotic Bacterial Count
- Increased Probiotic Bacterial Survival Through Upper Gastrointestinal Transit
- Increased Probiotic Co-existence
- Increased Probiotic Concentration in Stool
- Increased Probiotic Genus Proportion
- Increased Proportion of Aerobic and Anaerobic Bacteria
- Increased Protective Fecal Bifidobacterial Diversity
- Increased Relative Abundance of Beneficial Microbiota (Lactobacillus)
- Increased Safety of Probiotic Use
- Increased Salmonella Shedding
- Increased Specific Probiotic Strains
- Increased Stool Frequency
- Increased Stool Looseness
- Increased Total Bacterial Load
- Increased Total Fecal Bacterial Counts
- Increased Viable Bacteria Count
- Inhibited Pathogenic Microbes
- Inhibition of Harmful Bacterial Growth
- Maintained Antibiotic Susceptibility
- Maintained Gastrointestinal Microbiome Stability
- Maintained Gut Microbiome Composition
- Maintained Gut Microbiota Stability
- Maintained Normal Intestinal Microbiota
- Maintained Prevotella-Dominant Gut Microbiota
- Maintained Short-Chain Fatty Acid Levels During Antibiotic Treatment
- Maintenance of Therapeutic Probiotic Levels
- Microbial Community Characterization
- Microbiome Biomarker of Treatment Response
- Microbiome Remodeling
- Mitigated Microbiota Changes
- Moderate Impact on Main GI Bacterial Groups
- Modified Fecal Microbiota
- Modulated Bacterial Phenotypes
- Modulated Colonic Microbiota
- Modulated Gastrointestinal Microbiota
- Modulated Gut Microbial Diversity
- Modulated Gut Microbiota
- Modulation of Microbiota Activity
- No Change in Diarrhea Development in C. difficile-Positive Patients
- No Change in Diarrhea Duration
- No Change in Mouse Intestinal Flora Composition
- No Change in Severe Diarrhea Incidence
- No Demonstrated Efficacy for Isolated Bifidobacterium Use
- No Impact on Clostridium difficile Toxin Carriage
- No Reduction in Antibiotic-Resistant Organism Colonization
- No Reduction in Clostridioides difficile Infection
- No Reduction in Gastrointestinal Infections
- Non-Toxic Colonization
- Normalized Intestinal Microbiota
- Normalized Stool Type
- Potential Probiotic Benefits
- Potential Probiotic Health Effects
- Presence of Viable L. acidophilus La-5 Strains in Feces
- Preventative Gut Colonisation
- Prevented Bloodstream Infection
- Prevention of Antibiotic-Associated Diarrhea
- Prevention of C. difficile-Induced Diarrhea
- Prevention of Intestinal Dysbiosis
- Prevention of Intestinal Infections
- Probiotic Adherence Variability Based on Host Factors
- Protection Against Brush Border Damage Induced by Bacteria
- Protection Against Intestinal Epithelial Injury
- Protection of Colonic Mucosa from C. difficile Toxins
- Recovered Microbiome-associated Dysbiosis
- Recovery of BB-12 from Feces
- Reduced Abundance of Pro-Pathogenic Bacteria
- Reduced Acute Diarrhea Incidence
- Reduced Adhesion of Diarrheagenic Bacteria
- Reduced Antibiotic Damage to Microbiota
- Reduced Antibiotic-Associated Diarrhea
- Reduced Antibiotic-Associated Diarrhea Symptoms
- Reduced Antibiotic-Associated Diarrhoea in Children
- Reduced Antibiotic-Associated Gastrointestinal Complaints
- Reduced Antibiotic-Associated Gut Microbiome Disruption
- Reduced Antibiotic-Induced Gut Dysbiosis
- Reduced Antibiotic-Related Diarrhea
- Reduced Bacillus spp. Spore Count
- Reduced Bacteremia
- Reduced Bacterial Colonization
- Reduced Bacterial Load
- Reduced Bacterial Translocation to Mesenteric Lymph Nodes
- Reduced Bifidobacterial Population
- Reduced C. difficile Disease Recurrences
- Reduced Campylobacter jejuni Survival
- Reduced Clostridioides difficile Abundance
- Reduced Clostridioides difficile Infection
- Reduced Clostridium Counts
- Reduced Clostridium Difficile Adherence
- Reduced Clostridium Difficile Growth
- Reduced Clostridium Difficile Levels
- Reduced Clostridium Species Counts
- Reduced Clostridium difficile Count
- Reduced Clostridium difficile Cytotoxicity
- Reduced Clostridium difficile Infection
- Reduced Coliform Levels in the Jejunum
- Reduced Colonic Clostridium Species
- Reduced Colonization with Probiotic Lactobacilli
- Reduced Community-Acquired Gastrointestinal Infections
- Reduced Days with Defecation Urgency
- Reduced Days with Diarrhea
- Reduced Detection Rates of Clostridium
- Reduced Diarrhea
- Reduced Diarrhea Duration
- Reduced Diarrhea Episodes
- Reduced Diarrhea Incidence
- Reduced Diarrhea Incidence in Day Care Centers
- Reduced Diarrhea Incidence in Offspring
- Reduced Diarrhea Rate
- Reduced Diarrhea Recurrence
- Reduced Diarrhea Severity
- Reduced Diarrhea Symptoms
- Reduced Drug-Induced Enteropathy
- Reduced Duration of Acute Diarrhoea
- Reduced Duration of Acute Gastroenteritis
- Reduced Duration of Diarrhea Episodes
- Reduced Duration of Hospitalized Diarrhea in Children
- Reduced Duration of Nosocomial Infections
- Reduced E. coli Adherence in Gut
- Reduced EHEC Colonization
- Reduced Enterobacteriaceae Counts
- Reduced Enterobacteriaceae Levels in Feces
- Reduced Enterococci Levels
- Reduced Enteropathogen Activity
- Reduced Enteropathogen Adhesion
- Reduced Enteropathogen Colonization
- Reduced Enteropathogen Growth
- Reduced Enteropathogen Presence in Enterocyte Layer
- Reduced Enteropathogenic Bacteria
- Reduced Enteropathogenic Burden
- Reduced Enteropathogenic Infection Risk
- Reduced Enterotoxicity
- Reduced Escherichia coli Counts
- Reduced Expression of Lethal Toxin Genes
- Reduced Faecal Clostridium Population
- Reduced Fecal Clostridium Levels
- Reduced Fecal Clostridium difficile
- Reduced Fecal Coliform Count
- Reduced Fecal Enterococci
- Reduced Fecal Excretion of Clostridial Spores
- Reduced Fecal Excretion of Pathogenic Bacteria
- Reduced Fecal Metabolite Levels
- Reduced Fecal Odor
- Reduced Fluctuations in Intestinal Bacteria
- Reduced Gastrointestinal Adverse Event
- Reduced Gastrointestinal Adverse Events
- Reduced Gastrointestinal Coliforms
- Reduced Gastrointestinal Infections
- Reduced Growth of Harmful Bacteria
- Reduced Growth of Putrefactive Bacteria
- Reduced Harmful Bacteria Fecal Excretion
- Reduced Harmful Bacteria Species
- Reduced Harmful Bacteria in Intestinal Microbiota
- Reduced Harmful Bacterial Populations
- Reduced Harmful Gut Bacteria
- Reduced Harmful Microorganisms
- Reduced Hospitalization for Acute Gastroenteritis
- Reduced Incidence of Acute Colitis
- Reduced Incidence of Acute Diarrhoea
- Reduced Incidence of Antibiotic-Associated Diarrhea
- Reduced Incidence of Bacterial Infections
- Reduced Incidence of Clostridium Difficile Infection
- Reduced Incidence of Diarrhea in Pigs
- Reduced Incidence of Gastroenteritis
- Reduced Incidence of Gastrointestinal Tract Infection Symptoms
- Reduced Incidence of Loose Stools
- Reduced Incidence of Loose or Watery Stools
- Reduced Incidence of Severe Diarrhoea
- Reduced Infection Recurrence
- Reduced Infectious Complication
- Reduced Intestinal Colonization
- Reduced Intestinal Infections
- Reduced Intestinal Pathogen Bacterial Count
- Reduced Intestinal Pathogenic Bacteria
- Reduced Intestinal Pathogens
- Reduced Intestinal Salmonella Burden
- Reduced Intestinal Tissue Injury
- Reduced Intracellular pH of Pathogenic Bacteria
- Reduced Lecithinase-Positive Clostridium
- Reduced Levels of C. perfringens
- Reduced Nontransferable Antibiotic Resistance
- Reduced Nosocomial Diarrhea Incidence
- Reduced Odds of Probiotic Lactobacilli Successful Colonization
- Reduced Opportunistic Pathogenic Bacteria Levels
- Reduced Oral Rehydration Solution Use
- Reduced Pathogen Colonization
- Reduced Pathogen Count in Feces
- Reduced Pathogen Counts in Organs
- Reduced Pathogen Infection
- Reduced Pathogen Translocation to Visceral Tissues
- Reduced Pathogen Viability
- Reduced Pathogenic Bacteria
- Reduced Pathogenic Bacteria Adhesion
- Reduced Pathogenic Bacteria Levels
- Reduced Pathogenic Bacteria Load
- Reduced Pathogenic Bacteria in Gut
- Reduced Pathogenic Bacterial Abundance
- Reduced Pathogenic Bacterial Colonization
- Reduced Pathogenic Bacterial Growth
- Reduced Pathogenic Bacterial Load In Vivo
- Reduced Pathogenic Bacterial Populations
- Reduced Pathogenic Contamination
- Reduced Pathogenic Load
- Reduced Pathogenic Microorganisms in the Intestine
- Reduced Pathological Characteristics of the Intestinal Tract
- Reduced Potential Pathogenic Bacteria
- Reduced Prolonged Diarrhea
- Reduced Recovery Time for Diarrhea
- Reduced Recurrence Rate
- Reduced Recurrent Clostridioides Difficile Infection
- Reduced Recurrent Clostridioides difficile Infection Incidence
- Reduced Risk of Diarrhea
- Reduced Risk of Diarrhea on Day 4
- Reduced Risk of Prolonged Diarrhea
- Reduced Salmonella Typhimurium Activity
- Reduced Severe Necrotizing Enterocolitis (NEC)
- Reduced Severity of Gastroenteritis
- Reduced Stool pH
- Reduced Sulphite-Reducing Clostridia
- Reduced Total Bacterial Levels
- Reduced Toxin A-Receptor Binding
- Reduced Ubiquitous Bacteria Levels
- Reduced Virulence of Pathogens
- Reduced Virulence or Safety Concerns
- Reduced Virulence-Associated Activity
- Reduced Watery Stools
- Regulated Colonic Bacterial Flora
- Regulated Intestinal Microbiota
- Regulated Intestinal Microbiota Balance
- Regulated Microbiota Function
- Resolution of Diarrhea
- Resolved Moderate Diarrhea
- Restored Endogenous Microbiota Equilibrium
- Restored Gut Microbiota
- Restored Intestinal Microbiota Balance
- Restored Microbiome Composition
- Restored Normal Microbiota
- Restored Relative Abundance of Specific Bacteria
- Restored Short-Chain Fatty Acid Levels
- Reversed Microbiome Metabolic Changes
- Safety in Terms of Adverse Events
- Safety of Probiotic Supplementation
- Shortened Diarrhea Duration
- Similar Rate of Diarrhea
- Stabilized Fecal Microbiota
- Stable Antibiotic Susceptibility Profiles
- Strain Authentication and Identification
- Successful Gut Colonization
- Suppressed Pathogenic Growth
- Suppressed Salmonella Typhimurium Infection
- Synergistic Antibiotic Effect
- Temporary Intestinal Dominance of Lactobacillus paracasei A
- Transient Gut Colonization
- Transient Increase in Intestinal Lactobacillus Populations
- Unchanged Cell Numbers of Fecal Bacteria
- Unchanged Diarrhea Rate
- Unchanged Fecal Antibiotic Resistance
- Unchanged Incidence of Diarrhea
- Unchanged Intestinal Bacterial Concentrations
- Unchanged Severe Diarrhea
- Unchanged Total Anaerobes, Gram-negative Anaerobes, and Total Aerobes
- Unchanged Use of Antibiotics
- Viability of Probiotic Bacteria in Cheese
- Well Tolerated Probiotic
- White Blood Cell Count
- Worsened Fecal Scores